SCHEMBL20964591

SCHEMBL20964591

Cc1noc(C)c1CSc1ccccc1C(=O)N1CCN(c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.80
LMNA P02545 7/20 0.80
ALDH1A1 P00352 6/20 0.80
TSHR P16473 2/20 0.80
MAPT P10636 6/20 0.67
KMT2A Q03164 2/20 0.67
MEN1 O00255 1/20 0.67
PKM P14618 1/20 0.67
POLB P06746 2/20 0.53
HTT P42858 2/20 0.49
THRB P10828 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
NPC1 O15118 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
IDE P14735 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19745442 0.89 LMNA (1.00) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964561 0.87 MAPT (0.66) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964658 0.86 LMNA (0.82) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20965289 0.84 ALDH1A1 (0.67) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964557 0.84 LMNA (0.67) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964661 0.82 MAPT (0.71) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964680 0.82 LMNA (0.82) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964645 0.82 LMNA (0.82) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964690 0.82 ALDH1A1 (0.79) SMN1; SMN2LMNAALDH1A1TSHRKMT2A
SCHEMBL20964944 0.81 TSHR (0.77) SMN1; SMN2LMNAALDH1A1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 SMN1; SMN2 263/4885LMNA 1413/4885ALDH1A1 141/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 SMN1; SMN2 2477/4885LMNA 897/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.